Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Portopulmonary hypertension: an update.
Safdar Z, Bartolome S, Sussman N. Safdar Z, et al. Liver Transpl. 2012 Aug;18(8):881-91. doi: 10.1002/lt.23485. Liver Transpl. 2012. PMID: 22674534 Free article. Review.
Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial.
Preston IR, Burger CD, Bartolome S, Safdar Z, Krowka M, Sood N, Ford HJ, Battarjee WF, Chakinala MM, Gomberg-Maitland M, Hill NS. Preston IR, et al. Among authors: safdar z. J Heart Lung Transplant. 2020 May;39(5):464-472. doi: 10.1016/j.healun.2019.12.008. Epub 2020 Jan 21. J Heart Lung Transplant. 2020. PMID: 32008947 Clinical Trial.
Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR, Souza R, Waxman A, Escribano Subias P, Feldman J, Meyer G, Montani D, Olsson KM, Manimaran S, Barnes J, Linde PG, de Oliveira Pena J, Badesch DB; PULSAR Trial Investigators. Humbert M, et al. N Engl J Med. 2021 Apr 1;384(13):1204-1215. doi: 10.1056/NEJMoa2024277. N Engl J Med. 2021. PMID: 33789009 Clinical Trial.
Hospitalizations in patients with idiopathic pulmonary fibrosis.
Kim HJ, Snyder LD, Adegunsoye A, Neely ML, Bender S, White ES, Conoscenti CS, Strek ME; IPF-PRO Registry Investigators. Kim HJ, et al. Respir Res. 2021 Sep 30;22(1):257. doi: 10.1186/s12931-021-01851-4. Respir Res. 2021. PMID: 34592998 Free PMC article.
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.
Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Grünig E, Kopeć G, Meyer G, Olsson KM, Rosenkranz S, Xu Y, Miller B, Fowler M, Butler J, Koglin J, de Oliveira Pena J, Humbert M; STELLAR Trial Investigators. Hoeper MM, et al. N Engl J Med. 2023 Apr 20;388(16):1478-1490. doi: 10.1056/NEJMoa2213558. Epub 2023 Mar 6. N Engl J Med. 2023. PMID: 36877098 Clinical Trial.
Tadalafil therapy for pulmonary arterial hypertension.
Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Galiè N, et al. Among authors: safdar z. Circulation. 2009 Jun 9;119(22):2894-903. doi: 10.1161/CIRCULATIONAHA.108.839274. Epub 2009 May 26. Circulation. 2009. PMID: 19470885 Clinical Trial.
Plasma 15-F2t-isoprostane in idiopathic pulmonary arterial hypertension.
Zhang R, Sun ML, Fan YF, Jiang X, Zhao QH, He J, Wang L, Shailendra PK, Safdar Z, Jing ZC. Zhang R, et al. Among authors: safdar z. Int J Cardiol. 2014 Aug 1;175(2):268-73. doi: 10.1016/j.ijcard.2014.05.014. Epub 2014 May 17. Int J Cardiol. 2014. PMID: 24877587
83 results